CNS Pharmaceuticals (NASDAQ: CNSP) Scientific Advisory Board member Sigmund Hsu, MD, presented at the American Society of Clinical Oncology (“ASCO”) annual meeting. Hsu’s presentation focused on the company’s ongoing clinical trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). CNS Pharmaceuticals is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, and Berubicin is a novel anthracycline and the first that may cross the blood-brain barrier with central nervous system (“CNS”) uptake. Hsu presented during the meeting’s central nervous system tumors poster session. The company’s ongoing global study will ultimately involve some 240-plus adult participants and is an adaptive, multicenter, open-label, randomized, controlled study. Those involved in the study have recurrent glioblastoma multiforme who have experienced failure of standard first-line therapy. The study is assessing the efficacy and safety of Berubicin. The primary endpoint of this study is overall survival. “We are fully dedicated to advancing the development of Berubicin toward potentially providing an innovative and much-needed option for treatment in GBM, an area of significant unmet medical need,” said CNS Pharmaceuticals chief medical officer Dr. Sandra L. Silberman, MD, in the press release. “With this goal in mind, we consider that our global study, which has been thoughtfully designed based on prior data as well as input from key opinion leaders and feedback from the FDA, could potentially be pivotal. We also believe that valuable interactions with our investigators on this study, as well as our heartfelt consideration of the needs of patients has positioned us for a successful outcome. Moreover, the positive feedback we’ve received from the regulatory authorities across Europe for this trial bolsters confidence in our state-of-the-art trial design and will significantly expand our ability to reach these patients.”
To view the full press release, visit https://ibn.fm/s1bsz
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, an aggressive and incurable form of brain cancer. Additionally, CNS Pharmaceuticals is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain, pancreatic and ovarian cancers as well as lymphomas. For more information about the company, please visit www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.